Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

NCT02926638 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02926638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2/3
Overall status
Terminated
Start date
June 16, 2014
Completion date
October 12, 2016
Enrollment
9 (actual)
Sites
627

Conditions

As the registry lists them; a condition with its own page is linked.

met positive, recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7